Having trouble accessing articles? Reset your cache.

Congress clears CDER reorganization aimed at deepening FDA therapeutic expertise

Congress has signed off on an FDA reorganization that is intended to allow drug reviewers to develop greater expertise in both the diseases that are being treated and the technologies underlying new medicines.

The changes will create more senior positions and

Read the full 412 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE